Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and Brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.

Article  PubMed  PubMed Central  Google Scholar 

Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17:504–15.

Article  CAS  PubMed  Google Scholar 

Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3: e59125.

Article  PubMed  PubMed Central  Google Scholar 

Naito Y, Osa A, Masuhiro K, Hirai T, Koyama S, Kumanogoh A. Monitoring PD-1-blocking antibodies bound to T cells derived from a drop of peripheral blood. J Vis Exp. 2020. https://doi.org/10.3791/60608.

Article  PubMed  Google Scholar 

Kameoka Y, Akagi T, Murai K, Noji H, Kato Y, Sasaki O, et al. Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. Int J Hematol. 2018;108:510–5.

Article  CAS  PubMed  Google Scholar 

Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥ 2 immune-related adverse events in patients with cancer. J Immunother Cancer. 2020;8: e001622.

Article  PubMed  PubMed Central  Google Scholar 

Allouchery M, Beuvon C, Pérault-Pochat MC, Roblot P, Puyade M, Martin M. Safety of immune checkpoint inhibitor resumption after interruption for immune-related adverse events, a narrative review. Cancers (Basel). 2022;14:955.

Article  CAS  PubMed  Google Scholar 

Araujo DV, Uchoa B, Soto-Castillo JJ, Furlan LL, Oliva M. When less may be enough: dose selection strategies for immune checkpoint inhibitors focusing on AntiPD-(L)1 agents. Target Oncol. 2022;17:253–70.

Article  PubMed  Google Scholar 

Jiang M, Hu Y, Lin G, Chen C. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency. Shorter Course Front Oncol. 2022;12: 906251.

Article  CAS  PubMed  Google Scholar 

Lepik KV, Fedorova LV, Kondakova EV, Zalyalov YR, Babenko EV, Lepik EE, et al. A Phase 2 study of nivolumab using a fixed dose of 40 mg (Nivo40) in patients with relapsed/refractory Hodgkin lymphoma. Hemasphere. 2020;4: e480.

Article  PubMed  PubMed Central  Google Scholar 

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36:1428–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Damoiseaux J. The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor. Clin Immunol. 2020;218: 108515.

Article  CAS  PubMed  Google Scholar 

Takai R, Funakoshi Y, Suto H, Nagatani Y, Imamura Y, Toyoda M, et al. Serum soluble interleukin-2 receptor as a potential biomarker for immune-related adverse events. Anticancer Res. 2021;41:1021–6.

Article  CAS  PubMed  Google Scholar 

Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355:1423–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O’Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111:3220–4.

Article  CAS  PubMed  Google Scholar 

Veatch JR, Singhi N, Jesernig B, Paulson KG, Zalevsky J, Iaccucci E, et al. Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. J Immunother Cancer. 2020;8: e001591.

Article  PubMed  PubMed Central  Google Scholar 

Acharya N, Madi A, Zhang H, Klapholz M, Escobar G, Dulberg S, et al. Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity. 2020;53:658-71.e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taves MD, Ashwell JD. Glucocorticoids in T cell development, differentiation and function. Nat Rev Immunol. 2021;21:233–43.

Article  CAS  PubMed  Google Scholar 

Ogasawara R, Hashimoto D, Sugita J, Yamawaki F, Naka T, Mitsuhashi T, et al. Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma. Int J Hematol. 2020;111:475–9.

Article  CAS  PubMed  Google Scholar